The Democratic Republic of Congo initiated a vaccination campaign targeting front-line healthcare workers and other priority groups in response to an ongoing Ebola outbreak. The vaccination effort commenced in Kisangani and represents part of a broader containment strategy, according to health officials.
The campaign utilizes the Ervebo vaccine, with the DRC receiving 70,000 approved doses according to WHO figures. Over 50,000 doses have been distributed to date. However, the vaccine was developed and licensed for a different Ebola strain, and its protective capacity against the currently circulating Bundibugyo strain has not been established. Approximately 20,000 doses designated for the DRC will be allocated to clinical trials designed to evaluate vaccine effectiveness against the new strain. Health workers have publicly called for increased vaccine allocations.
The outbreak is concentrated in Ituri province, which shares a border with Uganda. Health authorities have indicated plans to vaccinate populations across neighboring provinces in a targeted expansion strategy moving outward from the outbreak epicenter. As of Tuesday, official government data documented 5,713 confirmed cases with 2,744 associated deaths.
The situation continues to deteriorate amid multiple complicating factors, including regional instability, displacement of populations, labor actions by health workers, and significant population movements that facilitate transmission. WHO assessments characterize the outbreak as uncontrolled and project it may eventually exceed the scale of the 2014-2016 West Africa Ebola epidemic, which resulted in more than 11,000 deaths across Guinea, Liberia, and Sierra Leone. Currently, no approved vaccines or treatments exist specifically for the Bundibugyo strain, with clinical development ongoing.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI